References of "Caron, P"
     in
Bookmark and Share    
See detailCorrelations of the High Resolution MRI aspect of GH-secreting pituitary adenomas prior to treatment
Potorac, I; PETROSSIANS, Patrick ULg; Schillo, F et al

in Abstract book - Symposium "Perspectives in Endocrinology" Congresses Highlights 2013:ECE Copenhagen, ENDO SF, SFE Paris (2014, February)

Detailed reference viewed: 10 (1 ULg)
Full Text
Peer Reviewed
See detailCorrelations of the High Resolution MRI aspect of GH-secreting pituitary adenomas prior to treatment
Potorac, Iulia ULg; PETROSSIANS, Patrick ULg; Schillo, F et al

in 23rd meeting of the Belgian Endocrine Society - Abstract book (2013, October 19)

Detailed reference viewed: 14 (1 ULg)
Full Text
Peer Reviewed
See detailCorrélations significatives de l'aspect en IRM haute résolution des adénomes hypophysairesà GH avant traitement
Potorac, Iulia ULg; PETROSSIANS, Patrick ULg; Schillo, F et al

in Annales d'Endocrinologie (2013, October), 74

Detailed reference viewed: 24 (2 ULg)
Full Text
Peer Reviewed
See detailClinical characterization of cabergoline resistant prolactinomas : a multicenter experience on 92 patients
VROONEN, Laurent ULg; Jaffrain Rea, ML; PETROSSIANS, Patrick ULg et al

in Annales d'Endocrinologie (2012, April), 73(2), 153

Detailed reference viewed: 26 (4 ULg)
Full Text
Peer Reviewed
See detailCyclin dependent kinase inhibitor (CDKN1B) gene variants in AIP mutation-negative familial isolated pituitary adenomas (FIPA) kindreds
Tichomirowa, M.; Lee, M.; Barlier, A. et al

in Endocrine-Related Cancer (2012), 19

Detailed reference viewed: 10 (4 ULg)
Full Text
Peer Reviewed
See detailProlactinomas Resistant to Standard Doses of Cabergoline : A multicenter study of 92 patients
VROONEN, Laurent ULg; Jaffrain-Rea, ML; PETROSSIANS, Patrick ULg et al

in European Journal of Endocrinology (2012), 167

Detailed reference viewed: 38 (9 ULg)
Full Text
See detailClinical characterization of cabergoline resistant prolactinomas : a multicenter experience on 92 patients
VROONEN, Laurent ULg; Jaffrain-Rea, M. L.; PETROSSIANS, Patrick ULg et al

in ENEA Munich - abstract book (2011, December)

Detailed reference viewed: 21 (4 ULg)
Full Text
Peer Reviewed
See detailGender-related differences in MEN1 lesion occurrence and diagnosis: a cohort study of 734 cases from the Groupe d''etude des Tumeurs Endocrines
goudet, p; Bonithon-Kopp, C.; Murat, A. et al

in European Journal of Endocrinology (2011)

Detailed reference viewed: 8 (1 ULg)
See detailFaut-il rechercher des anomalies génétiques constitutionnelles des gènes AIP et MEN1 chez un sujet jeune atteint d'adénome hypophysaire isolé sporadique ?
Cuny, T.; Pertuit, M.; Van bellinghen, J. F. et al

in Annales d'Endocrinologie - 28ème congrès de la société Française d'Endocrinologie (2011)

Detailed reference viewed: 7 (0 ULg)
Full Text
Peer Reviewed
See detailMutations AIP chez les jeunes patients en dessous de 30 ans avec adénome hypophysaire agressif
Beckers, Albert ULg; Tichomirowa, M.; Barlier, A. et al

in Annales d'Endocrinologie (2010, September), 71(5), 397

Detailed reference viewed: 20 (4 ULg)
Full Text
Peer Reviewed
See detailCaractéristiques des prolactinomes résistants aux agonistes dopaminergiques
Vroonen, Laurent ULg; Tamagno, G.; Naves, L. et al

in Annales d'Endocrinologie (2010, September), 71(5), 347

Detailed reference viewed: 26 (3 ULg)
Full Text
See detailMutations AIP chez les jeunes patients en-dessous de 30 ans avec adénome hypophysaire agressif
Beckers, Albert ULg; Tichomirowa, M.; Barlier, A. et al

in 27ème Congrès de la Société Française d'Endocrinologie - Deauville, 29 septembre - 2 octobre 2010 (2010, September)

Detailed reference viewed: 23 (4 ULg)
See detailCyclin dependent kinase inhibitor 1B (CDKN1B) gene mutations in FIPA
Tichomirowa, M. A.; Pellegata, N. S.; Barlier, A. et al

in European Neuroendocrine Association - Liège, 22-25 septembre 2010 (2010, September)

Detailed reference viewed: 17 (3 ULg)
See detailHigh Prevalence of AIP Gene Mutations Following Focussed Screening in Young Patients with Sporadic Pituitary Macroadenomas
Tichomirowa, M. A.; Barlier, A.; Daly, Adrian ULg et al

in European Neuroendocrine Association - Liège, 22-25 septembre 2010 (2010, September)

Detailed reference viewed: 14 (3 ULg)
See detailComprehensive study about the characteristics of 80 dopaminergic agonist resistants prolactinomas
Vroonen, Laurent ULg; Tamagno, G.; Naves, L. et al

in European Neuroendocrine Association - Liège, 22-25 septembre 2010 (2010, September)

Detailed reference viewed: 17 (5 ULg)
See detailCharacterization of prolatinomas resistant to dopaminergic agonists
Vroonen, Laurent ULg; Tamagno, G.; Naves, L. et al

in 19 Meeting of the Belgian Endocrine and Metabolic societies (2009)

Detailed reference viewed: 15 (2 ULg)
Full Text
Peer Reviewed
See detailOctreotide (long-acting release formulation) treatment in patients with graves' orbitopathy: clinical results of a four-month, randomized, placebo-controlled, double-blind study.
Wemeau, J. L.; Caron, P.; Beckers, Albert ULg et al

in Journal of Clinical Endocrinology and Metabolism (2005), 90(2), 841-848

There are few effective, safe modalities for the management of Graves' ophthalmopathy (GO), a cell-mediated immune comorbidity of thyroid disease. Somatostatin analogs inhibit lymphocyte proliferation and ... [more ▼]

There are few effective, safe modalities for the management of Graves' ophthalmopathy (GO), a cell-mediated immune comorbidity of thyroid disease. Somatostatin analogs inhibit lymphocyte proliferation and activation, and accumulate in the orbital tissue of patients with GO. A double-blind, placebo-controlled study of a long-acting somatostatin analog [16 wk of long-acting release formulation of octreotide (octreotide-LAR)] was conducted in 51 patients with mild active GO with the aim of preventing deterioration and precluding the need for more aggressive therapeutic modalities, such as glucocorticoids or radiotherapy. No treatment effect was observed for the primary end point (a composite parameter defining the outcome as either success or failure on the basis of changes in class/grade of the severity index and Clinical Activity Scale of GO). The Clinical Activity Scale score was reduced for patients treated with octreotide-LAR, but without any significant difference with respect to patients receiving placebo. However, octreotide-LAR significantly reduced proptosis (as measured by exophthalmometry). This was associated with nonsignificant differences in favor of octreotide-LAR in a series of proptosis-related parameters: class III grade, opening of the upper eyelid, the difference in ocular pressure between primary position and upgaze, and extraocular muscle involvement. By magnetic resonance imaging evaluation the extraocular muscle volumes appeared reduced, but nonsignificantly. No significant correlation between the initial uptake of the somatostatin analog indium-labeled and the response to treatment was observed. One patient in the octreotide-LAR group developed gallstones. In this study, octreotide-LAR did not seem suitable to mitigate activity in mild GO. Surprisingly, it significantly reduced proptosis, one of the most debilitating symptoms of GO. Additional studies are warranted to define the benefit to risk ratio of the somatostatin analogs in this indication. [less ▲]

Detailed reference viewed: 14 (2 ULg)
See detailA three-month course of depot octreotide in the treatment of Graves' orbitopathy : clinical results of a randomized placebo-controlled double-blind study
Wémeau, J. L.; Beckers, Albert ULg; Caron, P. et al

in 12th International Congress of Endocrinology - Abstract book (2004)

Detailed reference viewed: 1 (0 ULg)
See detailL'octréotide LP dans le traitement des ophtalmopathies basedowiennes incipiens : Evaluation prospective VS placebo
Wemeau, J. L.; Caron, P.; Rohmer, V. et al

in XXIème Congrès de la Société Française d'Endocrinologie - Abstract book (2004)

Detailed reference viewed: 6 (0 ULg)
Full Text
Peer Reviewed
See detailMarkers of tumor invasion are major predictive factors for the long-term outcome of corticotroph microadenomas treated by transsphenoidal adenomectomy.
Vallette-Kasic, S.; Dufour, H.; Mugnier, M. et al

in European Journal of Endocrinology (2000), 143(6), 761-8

OBJECTIVE: To assess the postsurgical outcome of patients with corticotroph microadenomas and to define predictors of the long-term outcome, with special emphasis on markers of tumor extension. DESIGN ... [more ▼]

OBJECTIVE: To assess the postsurgical outcome of patients with corticotroph microadenomas and to define predictors of the long-term outcome, with special emphasis on markers of tumor extension. DESIGN: Prospective study of 53 corticotroph microadenomas treated by enlarged adenomectomy. Patients followed for at least 2 years were classified into two groups: those in long-term remission and uncured patients (immediate failures and recurrences). Pre-, per- and postoperative parameters were analyzed as predictors of the long-term outcome. METHODS: Baseline hormone assessments were performed preoperatively, 8 days after surgery and every 6-12 months thereafter. Pituitary magnetic resonance imaging (MRI) allowed analysis of possible tumor extension to adjacent structures. Apparent completeness of the surgical removal was determined, and fragments labeled either 'tumor' or 'surrounding pituitary tissue' were submitted to serial sectioning. RESULTS: Immediate control of hypercortisolism was achieved in 43/53 patients (81%). However, later recurrences were observed in five patients (9%). Preoperative MRI showed tumor extension into adjacent structures with good specificity (91%) for prediction of surgical failure. Evidence of local invasion at surgery was also significantly predictive of the long-term outcome. A corticotroph adenoma was found at histological examination in 96% of the patients, and 26% had irregular limits, a feature significantly correlated with a poor outcome. Immediate postoperative plasma cortisol did not allow discrimination between long-term remissions and recurrences. CONCLUSION: Surgical failure was best predicted by signs of tumor 'invasiveness' at MRI, confirmed by peroperative examination and histology. [less ▲]

Detailed reference viewed: 14 (1 ULg)